SavedAdd your journal

Journals / Turkish Journal of Pharmaceutical Sciences / 2020 / Cilt: 17 - Sayı: 3

The Cardiopulmonary Effects of the Calcitonin Generelated Peptide Family

Kalsitonin-Geni İle İlişkili Peptit Ailesinin Kardiyopulmoner Etkileri

Banu Cahide TEL
Gökçen TELLİ
Bülent GÜMÜŞEL
Pages
349–356
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the roles of CGRP family members in cardiopulmonary diseasesare investigated based on the studies performed to date.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cardiopulmonary diseases are very common among the population.
📊
Key Findings & Data:Especially in recent years, two important members of the family, adrenomedullin and adrenomedullin2/intermedin, havebeen considered new treatment targets in cardiopulmonary diseases.
💡
Conclusion & Impact:In this review, the roles of CGRP family members in cardiopulmonary diseasesare investigated based on the studies performed to date.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cardiopulmonary diseases are very common among the population. They are high-cost diseases and there are still no definitive treatments. Theroles of members of the calcitonin-gene related-peptide (CGRP) family in treating cardiopulmonary diseases have been studied for many years andpromising results obtained. Especially in recent years, two important members of the family, adrenomedullin and adrenomedullin2/intermedin, havebeen considered new treatment targets in cardiopulmonary diseases. In this review, the roles of CGRP family members in cardiopulmonary diseasesare investigated based on the studies performed to date.

Özet

Kardiyopulmoner hastalıklar toplumda sık görülen, tedavi maliyeti oldukça yüksek ve halen kesin bir tedavisi bulunmayan hastalıklardır. Kalsitoningeni ile ilişkili peptit (CGRP) ailesinin üyelerinin bir çok kardiyopulmoner hastalıktaki rolleri uzun yıllardır çalışılmakta ve umut vadeden sonuçlar elde edilmektedir. Özellikle son yıllarda CGRP ailesine ait peptitlerden adrenomedullin ve intermedin kardiyopulmoner hastalıklarda yeni tedavi hedefleri olarak değerlendirilmektedir. Bu derleme ile CGRP ailesi peptitlerinin kardiyopulmoner hastalıklardaki rolleri günümüze kadar yapılan çalışmalar doğrultusunda incelenmiştir.

🔖

Cite This Article

TEL, B. C., TELLİ, G., GÜMÜŞEL, B. (2022). The Cardiopulmonary Effects of the Calcitonin Generelated Peptide Family. Turkish Journal of Pharmaceutical Sciences, Cilt: 17 - Sayı: 3, 349–356. https://ajindex.com/articles/613722

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Born W, Fischer JA. The Calcitonin Peptide Family: What Can We Learn from Receptor Knock Out and Transgenic Mice. In: Hay DL, Dickerson IM, eds. The Calcitonin Gene-related Peptide Family Form, Function and Future Perspectives. Springer Dordrecht Heidelberg London New York; Springer; 2010:75-86
  2. Ghatta S, Ramarao P. Increased contractile responses to 5-Hydroxytryptamine and Angiotensin II in high fat diet fed rat thoracic aorta. Lipids Health Dis. 2004;3:19
  3. Wimalawansa SJ. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol. 1997;11:167-239
  4. Muff R, Born W, Fischer JA. Adrenomedullin and related peptides: receptors and accessory proteins. Peptides. 2001;22:1765-1772
  5. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004;84:903-934
  6. Ren YS, Yang JH, Zhang J, Pan CS, Yang J, Zhao J, Pang YZ, Tang CS, Qi YF. Intermedin 1-53 in central nervous system elevates arterial blood pressure in rats. Peptides. 2006;27:74-79
  7. Zhang SY, Xu MJ, Wang X. Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases. Br J Pharmacol. 2018;175:1230-1240
  8. Nagaya N, Kangawa K. Adrenomedullin in the treatment of pulmonary hypertension. Peptides. 2004;25:2013-2018
  9. Raja SG, Raja SM. Treating pulmonary arterial hypertension: current treatments and future prospects. Ther Adv Chronic Dis. 2011;2:359- 370
  10. Copp DH. Calcitonin: discovery, development, and clinical application. Clin Invest Med. 1994;17:268-277
  11. Copp DH, Cameron EC. Demonstration of a hypocalcemic factor (calcitonin) in commercial parathyroid extract. Science. 1961;134:2038
  12. Westermark P, Wernstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun. 1986;140:827- 831
  13. Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94:1099- 1142
  14. Kitamura K, Sakata J, Kangawa K, Kojima M, Matsuo H, Eto T. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun. 1993;194:720-725
  15. Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, Matsuo H. Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. Bioc